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The missing layer’’disorders, and cancers of the gastrointestinal tract and female
breast. Of these additional target tissues, most compelling exper-
imental evidence exists for the involvement of autophagy in the
development of pancreatitis [11]. It is also apparent that the
mechanisms that link autophagy to pancreatitis actually suggest
that inhibition of autophagy impairs the development of acute
pancreatitis, or more importantly improves its course once the
process has started [12]. Very limited experimental evidence
exists to determine whether autophagy plays a role in alcohol’s
adverse effects in the remaining target tissues. Thus, we believe
it may be premature to regard autophagy as the central mecha-
nism that connects key toxicity mediators and molecular mecha-
nisms with alcohol-induced histopathological disturbances in
tissues other than the liver.
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Open access under CC BY-NC-ND license.Autophagy: One of the molecular mechanisms of response to
intra-cellular stress in alcohol toxicity
To the Editor:
We appreciate the interest of Eid et al. [1] in the Hepatology
Snapshot on ‘‘Alcohol and toxicity’’ [2]. The authors posit that
autophagy, a physiological mechanism that is ubiquitous and
critical for maintaining balance in synthesis, degradation, and
recycling of proteins, lipids and other macromolecules, repre-
sents the central mechanism that connects key toxicity mediators
and molecular mechanisms with alcohol-induced disturbances in
target tissues.
Changes in the rate of autophagy are triggered by cell stress
and may ultimately result in the autophagic cell death [3]. Abnor-
mal autophagy is now widely implicated in human diseases (e.g.,
cancer, metabolic and neurodegenerative disorders, cardiovascu-
lar and pulmonary ailments) and in aging [4]. Multiple molecular
events that are known to regulate autophagy [5], such as mis-
folded proteins, oxidative stress, disruption of lipid and energy
metabolism, are indeed part of alcohol-induced pathophysiology
in target tissues.
Recent studies suggest that dysregulated autophagy could
play a role in most liver diseases such as chronic viral hepatitis
B and C, alcoholic and non-alcoholic fatty liver disease, and hepa-
tocellular carcinoma [6]. Among them, alcoholic liver disease has
been extensively studied, mostly at the experimental level [7].
Alcohol can both induce and suppress autophagy via different
molecular pathways including mTOR, phosphatase and tensin
homolog (PTEN) and AMP-activated protein kinase (AMPK) [8].
For example, alcohol may suppress the autophagic process by
inhibiting the activity of AMPK, resulting in an impaired clear-
ance of Mallory Denk bodies [8,9]. The complexities of the effects
of alcohol on autophagy are probably due to the fact that autoph-
agy is a complex process that may involve non-overlapping trig-
gers, effectors, and outcomes [7]. Such contradiction also
emerged from studies on the role of autophagy in cancer, where
autophagy was shown to be both a tumor-suppression pathway,
and a pro-survival mechanism that protects cancer cells [8].
Based on recent experimental studies [12], it has been
proposed that promoting autophagy represents a promising ther-
apeutic approach in patients with chronic liver diseases [6]. We
think that the current enthusiasm on this strategy should be tem-
pered. First, most data linking liver disease and autophagy derive
from experimental models, and translational studies in humans
are needed. Second, suppressed autophagy can represent a defen-
sive mechanism of the liver against the metabolic syndrome [10].
And most importantly, prolonged use of drugs interfering with
autophagy can lead to severe side effects including impaired liver
regeneration and promotion of hepatocellular carcinoma.
In addition, it is less clear what role autophagy may play in
alcohol-associated diseases in other tissues and organs. As
detailed in Rusyn and Bataller [2], in addition to liver disease,
excessive alcohol intake has been linked to pancreatitis, cardio-ey and neurological diseases, fetal alcohol spectrum
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Mother-to-infant transmission of hepatitis B
virus infection: Signiﬁcance of maternal viral load and
strategies for intervention
To the Editor:
We read with great interest the paper by Wen et al. [1], prospec-
tively evaluating hepatitis B viral load as a signiﬁcant factor for
immunoprophylaxis failure of infants born of hepatitis B surface
antigen (HBsAg) positive mothers. The authors suggested that the
risk of immunoprophylaxis failure increased with increasing viral
load and that intervention, such as anti-viral therapy in mothers
with high viral load, may be considered. We agreed with the
authors that high maternal viral load correlated with an
increased risk of vertical transmission, but the optimal cut-off
was yet to be determined [2]. However, we believed that further
clariﬁcation of the data would be needed before change in clinical
practice can be recommended.
First of all, the timing of blood test on the viral load of the sub-
jects was not clearly stated. The authors mentioned that it was
checked in the third trimester or within 2 months after delivery.
However, the viral load may vary throughout pregnancy and after
delivery. In a retrospective study which evaluated the change of
viral load in 33 HBsAg positive mothers, of whom 9 were hepati-
tis B e antigen (HBeAg) positive, it was found that viral load
increased by a mean of 0.4 log in late pregnancy or early postpar-
tum, of which four HBeAg negative mothers had >1 log change
during pregnancy [3]. In another retrospective study, ter Borg
et al. studied 38 HBsAg pregnancies of which 24 were HBeAg
positive. Lamivudine was started in the third trimester to reduce
the viral load in 13 pregnancies. The median viral load increased
from 7.8 log10 copies/ml before, to 8.2 log10 copies/ml during
pregnancy, and then decreased to 6.8 log10 copies/ml after deliv-
ery [4]. We were not told the reason why a proportion of the
women’s blood tests were collected after delivery for viral load
testing and not before delivery, in this prospective study. Assum-
ing the postpartum viral load to be similar to the antenatal level
may give rise to a wrong conclusion. Therefore, it would be
important for the authors to provide the median gestational
weeks when the blood test was taken, and to clarify the propor-
tion of mothers having postpartum test. Furthermore, as the
authors also pointed out, the result would be more meaningful
if the viral load levels were obtained before 28 weeks of gesta-
tion. Anti-viral therapy was started from 28 weeks of gestation
in most of the trials evaluating the efﬁcacy of anti-viral treatment
to decrease the risk of immunoprophylaxis failure in women with
high viral load [5]. Viral load quantiﬁcation in the late third tri-
mester, at delivery, or even after delivery, would be less useful
clinically as intervention to alter outcome may not be possible.
Caesarean delivery could not decrease the risk of immunopro-
phylaxis failure [2] and late viral load quantiﬁcation would not
allow adequate time for anti-viral treatment to decrease viral
load.
Secondly, we also wondered if any subjects were receiving
anti-viral therapy during the studied period. Anti-viral therapy
initiated after the blood test before delivery, or vice versa, could
affect the viral load level and subsequent correlation with risk
of the immunoprophylaxis failure. Thirdly, horizontal transmis-
sion of hepatitis B virus was possible [6] in 17.5% of children
who were tested for HBsAg at 1–3 years of age. The HBsAg posi-
tive status in this group could be due to horizontal infection
rather than genuine immunoprophylaxis failure. Finally, we were
interested in the high rate of invasive prenatal diagnostic test
(amniocentesis/CVS) and ﬁrst vaccine given beyond 24 hours in
the ten infants who suffered from chronic hepatitis B infection.
Could these be the potential factors that led to a higher rate of
immunoprophylaxis failure? We hope the authors could provide
more data on that.
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